HighMark Wealth Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

HighMark Wealth Management’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597K	Hold	35,196	–	–	0.2%	47
2026 Q1	$522K	Sell	35,196 -500	-1%	-$7.31K	0.21%	52
2025 Q4	$569K	Sell	35,696 -2,000	-5%	-$28.4K	0.23%	47
2025 Q3	$417K	Buy	37,696 +16,000	+74%	+$175K	0.18%	53
2025 Q2	$184K	Hold	21,696	–	–	0.09%	77
2025 Q1	$174K	Hold	21,696	–	–	0.1%	60
2024 Q4	$195K	Hold	21,696	–	–	0.11%	56
2024 Q3	$159K	Sell	21,696 -69,500	-76%	-$431K	0.09%	79
2024 Q2	$521K	Buy	91,196 +16,000	+21%	+$84.3K	0.31%	39
2024 Q1	$377K	Buy	75,196 +2,197	+3%	+$14.9K	0.23%	44
2023 Q4	$656K	Buy	72,999 +13,000	+22%	+$107K	0.48%	23
2023 Q3	$466K	Sell	59,999 -2,500	-4%	-$24.4K	0.39%	27
2023 Q2	$605K	Sell	62,499 -2,000	-3%	-$20.8K	0.45%	24
2023 Q1	$707K	Buy	64,499 +27,000	+72%	+$238K	0.55%	24
2022 Q4	$162K	Hold	37,499	–	–	0.12%	58
2022 Q3	$282K	Hold	37,499	–	–	0.24%	32
2022 Q2	$377K	Hold	37,499	–	–	0.3%	31
2022 Q1	$464K	Sell	37,499 -13,000	-26%	-$201K	0.31%	30
2021 Q4	$1.16M	Sell	50,499 -70	-0.1%	-$1.66K	0.73%	18
2021 Q3	$1.12M	Buy	50,569 +3,215	+7%	+$51K	0.82%	16
2021 Q2	$614K	Buy	+47,354	New	+$603K	0.45%	21
2021 Q1	–	Sell	-16,266	Closed	-$225K	–	477
2020 Q4	$225K	Hold	16,266	–	–	0.19%	40
2020 Q3	$240K	Sell	16,266 -750	-4%	-$10.9K	0.22%	39
2020 Q2	$277K	Hold	17,016	–	–	0.3%	32
2020 Q1	$246K	Sell	17,016 -300	-2%	-$5.29K	0.3%	28
2019 Q4	$350K	Buy	+17,316	New	+$160K	0.37%	23

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighMark Wealth Management's AUPH Position: Q2 2026 in Review

HighMark Wealth Management held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 35,196 shares worth $597K. The position accounts for 0.2% of the portfolio, ranked #47.

HighMark Wealth Management first reported a position in AUPH in Q4 2019 and has held it in 26 quarters since. The position peaked at $1.16M in Q4 2021. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

HighMark Wealth Management held 35,196 shares of Aurinia Pharmaceuticals worth $597K as of Q2 2026.
HighMark Wealth Management left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
Aurinia Pharmaceuticals made up 0.2% of HighMark Wealth Management's portfolio in Q2 2026, its #47 holding.
HighMark Wealth Management first reported a position in Aurinia Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
HighMark Wealth Management's Aurinia Pharmaceuticals position peaked at $1.16M in Q4 2021.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.